Key facts
- It has raised $6.7M; the latest was Later Stage VC ($2.0M) in Sep 2025.
- Notable investors include Antler, Invest International, Achmea Innovation Fund, Adeline Lee, Antler (Accessories) — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Clear.bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Clear.bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Clear.bio
Developer of a healthy diet initiative digital therapeutics designed to help users understand their body and make thorough decisions about lifestyle. The company's platform provides a personalized nutrition plan based on expert knowledge and real-time insights using body data via the sensor food to be prescribed to patients as soon as they are diagnosed with diabetes, enabling consumers to reduce the risk of disease and get continuous insights about their health.
- Sector
- Healthcare
- HQ
- Amsterdam, Netherlands
- Founded
- 2019
- Employees
- 20
- Website
- clear.bio/
- Ownership
- Privately Held (backing)
Clear.bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Clear.bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Clear.bio in its N-PORT filings yet. We sweep new filings monthly.